Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mattia Moratti has a total of 154 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Refractory autoimmune hemolytic anemia with poor erythropoietic compensation in combined immunodeficiency: A case series

    by Letizia Baldini, Mattia Moratti, Alessandro Ruggi, Francesco Licciardi, Fraia Melchionda, Maura Fois, Maria Elena Cantarini, Elena Facchini, Veronica Barat, Giovanni Del Borrello, et al.

  • Open Access

    Unexpected genetically determined immune dysregulation with liver involvement: GIMAP5 therapeutic dilemmas between targeted therapy and HSCT

    by Mattia Moratti, Michele La Manna, Lucia Colucci, Cristina Cifaldi, Silvia Di Cesare, Gioacchino Andrea Rotulo, Beatrice Rivalta, Donato Amodio, Andrea Pietrobattista, Andrés Caballero-Oteyza, et al.

    Introduction: Biallelic loss-of-function mutations in the GTPase of immunity-associated protein 5 ( GIMAP5 ) cause a severe syndrome characterized by altered immunity, lymphoproliferation, and progressive hepatopathy. This study aims to delineate the immunophenotypic signatures and clinical management of this deficiency by reporting the first Italian pediatric case alongside his mono-allelic carrier twin, integrated with a review of twenty previously published patients. Methods: We utilized trio-based clinical exome sequencing, flow cytometric immunophenotyping, protein expression profiling, and curated database analysis to evaluate the clinical trajectories. Results: The 11-year-old proband presented with autoimmune cytopenias, severe viral infections, and early biochemical liver anomalies. Genetic analysis identified compound heterozygous variants (p.Leu204Pro and p.Arg214Ter) in GIMAP5 gene resulting in absent protein expression, alongside an expanded atypical memory B-cell population and T-cell exhaustion. Notably, his dizygotic twin harbored the heterozygous p.Leu204Pro variant and exhibited decreased protein expression coupled with a localized fibro-adipose vascular anomaly, but lacked immune defects. Discussion: This observation suggests complex genotype-phenotype interactions, raising the question of whether partial GIMAP5 deficiency might subtly predispose to localized vascular anomalies under specific environmental or epigenetic conditions, likely requiring multi-hit mechanisms. Therapeutically, the proband achieved sustained clinical remission of cytopenias through immunomodulation with the mTOR inhibitor sirolimus. These findings expand the phenotypic spectrum of this disorder, underscoring a dual role in immune and endothelial homeostasis. Furthermore, the successful application of sirolimus highlights the efficacy of precision medical management as a viable strategy to stabilize patients, allowing time to carefully weigh the risks and benefits of definitive interventions, such as hematopoietic stem cell transplantation.

  • Immunodeficienza combinata grave: gestione intensivistica di un caso complicato da sepsi e coagulopatia severa

    by Ian Valencic, Mattia Moratti, Silvia Bettelli, Gina Ancora

    Severe combined immunodeficiency (SCID) is characterised by profound quantitative and/or functional T-cell defects and predisposes infants to life-threatening infections, including sepsis that may progress to organ dysfunction and disseminated intravascular coagulation (DIC) with thrombotic and haemorrhagic complications. However, atypical forms such as Omenn syndrome or leaky SCID may present with immune dysregulation and tissue inflammation, complicating the clinical picture. Starting from a clinical case of sepsis in an infant with SCID, a targeted literature review on emergency management of severely immunocompromised patients was performed to improve recognition and management of the critically ill infant with SCID, underscore the role of lymphopenia as a sentinel marker and propose practical recommendations to optimise outcomes in septic complications such as haemodynamic instability and DIC. Managing critically ill infants with SCID requires a coordinated multidisciplinary team (anaesthetist/intensivist, paediatrician, immunologist, transfusion specialist) able to apply resuscitation bundles while balancing infection risks. Each paediatric emergency unit should adopt a local protocol for urgent vascular access selection consistent with best-practice guidance and available resources.

  • Top Cited Papers
    Open Access

    Autoantibodies neutralizing type I IFNs in 40% of patients with WNV encephalitis in seven new cohorts

    by Adrian Gervais, Francesca Trespidi, Alessandro Ferrari, Francesca Rovida, Astrid Marchal, Stefania Croce, Irene Cassaniti, Mattia Moratti, Jennifer L. Uhrlaub, David M. Florian, et al.

    Mosquito-borne West Nile virus (WNV) infection is a growing global health problem. About 0.5% of infected individuals develop encephalitis. We previously showed that 40% of patients in six cohorts had WNV encephalitis because of circulating autoantibodies (auto-Abs) neutralizing type I IFNs. In seven new cohorts, we found that the prevalence of auto-Abs was highest (40% [17–44%]) in patients with encephalitis and very low in a small sample of individuals with asymptomatic or mild infection. In the 13 European, Middle Eastern, and American cohorts available, odds ratios (OR) for WNV encephalitis in individuals with these auto-Abs relative to those without them in a large sample of the general population untested for WNV infection range from ∼20 (OR = 17.7; 95% CI: 13.8–22.8, P < 10−16) for auto-Abs neutralizing only 100 pg/ml IFN-α2 and/or IFN-ω to >2,000 (OR = 2,218.4; 95% CI: 125.1–39,337.7, P < 10−16) for auto-Abs neutralizing high concentrations of IFN-α2 and high or low concentrations of IFN-ω. Preexisting auto-Abs neutralizing type I IFNs are therefore causal for WNV encephalitis in about 40% of patients.


  • Top Cited Papers
    Open Access

    Lymphoproliferation in inborn errors of immunity: From challenging diagnosis to histologic revision

    by Mattia Moratti, Beatrice Rivalta, Antonello Cardoni, Veronica Santilli, Enrico Attardi, Emma Concetta Manno, Riccardo Ciudino, Silvia Di Cesare, Cristina Cifaldi, Chiara Mengoli, et al.

    Inborn errors of immunity (IEI) are genetic disorders that not only heighten infection risk but also disrupt immune regulation, frequently leading to lymphoid tissue overgrowth known as lymphoid proliferations (LPD). We retrospectively reviewed 38 patients with genetically or clinically confirmed IEI and persistent LPD, comparing those with nonneoplastic/reactive hyperplasia to those who developed overt lymphoid neoplasm (lymphoma). Overall, 26% developed lymphoma—predominantly classical Hodgkin lymphoma or diffuse large B cell lymphoma—often after earlier IEI onset. Immunophenotyping and principal component analysis revealed that patients with common variable immunodeficiency developing Hodgkin lymphoma shared a distinctive T cell profile, differing from immunocompetent lymphoma cases. Centralized histologic re-evaluation reclassified several presumed lymphoma as nonneoplastic/reactive hyperplasia and identified Castleman-like and germinal center transformation patterns in nonneoplastic/reactive LPD. Notably, elevated blood IgM and circulating T follicular helper cells mirrored IgM deposits and PD-1+ T cells in lymph nodes. These findings highlight the importance of an integrated approach involving clinical, genetic, and pathological reviews to improve IEI diagnosis and avoid overtreatment.


  • Open Access

    MOG IgG3-Subclass Antibodies in MOG-Associated Disease

    by Anna Fetta, Francesca Conti, Agnese Lopalco, Chiara Corsini, Mattia Moratti, Luana Morelli, Fortuna Ricciardiello, Francesco Toni, Marcello Lanari, Rocco Liguori, et al.

    This report details a pediatric case of myelin oligodendrocyte glycoprotein antibody disease (MOGAD) characterized by isolated MOG-IgG3 positivity and IgG1 deficiency, highlighting a unique serologic profile and exploring its immunologic significance. In addition, a review of MOGAD cases with isolated MOG-IgG3 antibodies is included. A 12-year-old boy presenting with a progressive neurologic syndrome underwent clinical, radiologic, and laboratory evaluation. MRI showed extensive brain and spinal lesions. MOG-IgG3 antibodies were identified in serum and CSF by live cell-based assay, while other MOG-IgG subclasses were not detected. Serum IgG1 was low at baseline and throughout follow-up. First-line immunotherapy treatment led to significant improvement, with no relapses at 2-year follow-up. This case highlights the potential role of subclinical IgG1 deficiency in shaping the predominance or selective detection of MOG-IgG3 in MOGAD. While most MOG antibodies are predominantly of the IgG1 isotype, our review identified a few cases with isolated MOG-IgG3 antibodies. A possible contribution to pathogenesis cannot be excluded, and the patient's inability to produce a balanced IgG subclass profile could have favored a sustained IgG3 response. Larger studies are needed to clarify the clinical significance of MOG-IgG3 in MOGAD.

  • Open Access

    Neuroinflammation in CTLA-4 Haploinsufficiency: Case Report of a New Variant with Remarkable Response to Targeted Therapy

    by Letizia Baldini, Lucia Del Vecchio, Sara Cerasi, Anna Fetta, Mattia Moratti, Alessandra Bezzi, Simona Ferrari, Guido Di Dalmazi, Simone Rossi, Francesco Toni, et al.

    Inborn errors of immunity (IEI) encompass a diverse group of genetic disorders that often present with complex and multifaceted clinical features, including neuroinflammation. CTLA-4 deficiency (CTLA-4d), caused by monoallelic germline mutations in the CTLA4 gene, manifests with autoimmune phenomena, lymphoproliferation, infections, and neurological involvement in up to 30% of patients, with a broad clinical spectrum, ranging from encephalitis to demyelination and lymphocytic infiltration. Imaging typically shows multifocal contrast-enhancing lesions. Early recognition of CTLA-4d is crucial to guide clinical management. Herein, we report the case of a 15-year-old girl presenting with severe multifocal neuroinflammatory lesions, recurrent infections, and systemic granulomatous disease. After extensive infectious and immunological workup, a heterozygous de novo CTLA4 variant c.394G>A_p.Glu132Lys was identified and its pathogenicity confirmed by transendocytosis functional assays. Based on the genetic diagnosis, the patient was started on abatacept, with brilliant clinical and radiological results after dose adjustment. This report describes a new pathogenic variant of the CTLA4 gene and highlights the importance of considering IEIs, such as CTLA-4d, in patients with unexplained severe neuroinflammation. Also, it highlights the efficacy and tolerability of abatacept as a targeted therapy for neuroinflammation in CTLA4-d.


  • Infezioni herpetiche invasive neonatali

    by Ian Valencic, Mattia Moratti, Francesca Conti, Francesca Nanni, Gina Ancora

    Herpetic infection is a condition with high rates of neonatal morbidity and mortality; to date, there is no universally recognized strategy for the perinatal management of the risk of Herpes Simplex Virus (HSV) transmission based on the prognostic value attributed to maternal risk factors. Starting from the analysis of a clinical case of neonatal herpes meningoencephalitis, a literature review was conducted concerning the management of herpetic infection during pregnancy and in the neonatal period in terms of prevention and early diagnosis. The paper describes a case of a newborn with neonatal herpes meningoencephalitis transmitted by a mother with recurrent herpetic infection without clinically evident genital lesions at birth, despite the correct application of gynecological-neonatal protocols stratified by risk categories. An integrative model to the current guidelines should consider the following prophylactic strategies: performance of serological screening for HSV between the 24th and 28th week of pregnancy; provision of counseling regarding the main maternal-fetal and neonatal transmission risk factors for HSV; administration of antiviral prophylaxis with acyclovir to seropositive pregnant women starting from the 36th week of gestation; expansion of neonatal HSV-related screening tests even in cases where primary or recurrent genital lesions are present within ninety days before delivery. The diagnosis of neonatal herpetic meningoencephalitis suggests an underlying congenital error in innate immunity, related to an alteration in the TLR3/IFNα-β-λ axis, which presents with minimal/absent alterations in the immunological balance of I/II level, associated with infectious susceptibility to a restricted spectrum of viral pathogens, and deserves early immunological specialist evaluation.

  • Open Access

    Expert insights on Hodgkin’s lymphoma development in an activated PI3K delta syndrome patient undergoing leniolisib treatment

    by Francesca Conti, Mattia Moratti, Elena Sabattini, Pier Luigi Zinzani

    Activated PI3K delta syndrome (APDS) is a primary immunodeficiency that is caused by mutations in the PI3K signalling pathway resulting in either gain-of-function or loss-of-function phenotypes of APDS 1 and 2. Malignancy is one of the most serious complications associated with APDS patients, with the most commonly occurring of these being lymphoma, and is the most common cause of death in APDS patients. Management of APDS is complex and variable due to the heterogeneous nature of the disease and ranges from antimicrobial and immunosuppressant agents to haematopoetic stem cell transplantation. More recently, an increasing level of interest has been shown in the use of more targeted agents such as PI3Kδ-specific inhibitors. Here, we provide expert perspective on the suspected causality of a case of lymphoma observed in a 20-year-old female patient who was included in a clinical trial of leniolisib, a PI3K inhibitor.


  • Una sindrome infiammatoria multisistemica fredda complicata da shock

    by Ian Valencic, Mattia Moratti, Francesca Lombardi, Rosa Francavilla, Chiara Ghizzi

    Rivista di formazione e di aggiornamento professionale del pediatra e del medico di base, realizzata in collaborazione con l'Associazione Culturale Pediatri